BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Wednesday reported a loss of $24.4 million in its second quarter.

On a per-share basis, the Berkeley, California-based company said it had a loss of 31 cents.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.

The drug developer posted revenue of $2.6 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $3.7 million.

Aduro Biotech shares have decreased 28 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $5.40, a decrease of 57 percent in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ADRO at

blog comments powered by Disqus